[The new WHO classification of XXXX 2000. Pathology and genetics].

@entity424 @entity979 @entity5 @entity5606 @entity11 @entity1653 @entity76 @entity11809 @entity4847 @entity2946
New developments in neuro-oncology have prompted an update of the World Health Organization (WHO) classification of @entity11809 . Major changes include the addition of new entities and the refinement of criteria for the diagnosis and grading of various @entity5 , in particular the @entity1653 . As novel clinico-pathological entities, the @entity11 of the third ventricle, the atypical @entity5606 (AT/RT), the solitary fibrous tumor, and the @entity4847 have been listed. The former @entity2946 of the cerebellum, previously incorporated in the family of @entity5 , is now classified as @entity76 . The term mixed @entity979 / @entity979 has been replaced by @entity979 of intermediate differentiation. Furthermore, the large cell @entity2946 and the @entity424 were established as @entity5 variants. A separate chapter on the peripheral @entity5 has now been included in the classification. Substantial revisions were introduced in the @entity1653 chapter. For both @entity1653 WHO grade II and @entity1653 WHO grade III, histopathological criteria are now precisely defined. An important new addition to the WHO 2000 classification of nervous @entity5 is the inclusion of molecular pathology findings. With this combination of pathology and genetics it has set the stage for a new format of the WHO tumor classification series.
